PC
LSBPW

Periscope Capital’s LakeShore Biopharma Warrants LSBPW Stock Holding History

Periscope Capital’s Portfolio LSBPW Stock Details LSBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100,000
Closed -$15.6K – 704
2023
Q1 		$15.6K Buy
+100,000
New +$15.2K ﹤0.01% 679

Other funds holding LSBPW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
VAM
Valliance Asset Management Central, Hong Kong $122M AUM 362.1% 1-Year Est. Return
BP
BFAM Partners Northpoint, Hong Kong, Hong Kong $44K AUM 8.69% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SLM
Snow Lake Management Menlo Park, California $90.7M AUM 72.65% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Periscope Capital's LSBPW Position: Q2 2023 in Review

Periscope Capital sold out of LakeShore Biopharma Warrants (LSBPW) in Q2 2023, closing a stake of 100,000 shares — an estimated $15.6K sold.

Periscope Capital first reported a position in LSBPW in Q1 2023 and held it in 1 quarter. The position peaked at $15.6K in Q1 2023. 31 funds tracked by Wall St. Rank hold LSBPW as of Q2 2023.

  • Periscope Capital reported no remaining LakeShore Biopharma Warrants position as of Q2 2023 after selling out during the quarter.
  • Periscope Capital sold 100,000 LakeShore Biopharma Warrants shares in Q2 2023, an estimated $15.6K.
  • Periscope Capital first reported a position in LakeShore Biopharma Warrants in Q1 2023 and held it in 1 quarter.
  • Periscope Capital's LakeShore Biopharma Warrants position peaked at $15.6K in Q1 2023.
  • 31 funds tracked by Wall St. Rank held LakeShore Biopharma Warrants as of Q2 2023.

Based on Periscope Capital's 13F filing for Q2 2023, filed 14 Aug 2023.